Cardiovascular disease mortality and years of life lost attributable to non-optimal systolic blood pressure and hypertension in Northeastern Iran

Archives of Iranian Medicine

Volumn 18, Issue 3, 2015, Pages 144-152

  Sepanlou, Sadaf G ^a   Newson, Roger B ^b   Poustchi, Hossein ^a   Malekzadeh, Masoud M ^a   Rezanejad Asl, Parisa ^a   Etemadi, Arash ^a,c   Khademi, Hooman ^a,d   Islami, Farhad ^a,e   Pourshams, Akram ^a   Pharoah, Paul D ^f   Abnet, Christian C ^c   Brennan, Paul ^d   Bofetta, Paolo ^g   Dawsey, Sanford M ^c   Kamangar, Farin ^a,h   Malekzadeh, Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e AMERICAN CANCER SOCIETY   (United States)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h MORGAN STATE UNIVERSITY   (United States)

Author keywords

Blood pressure; Hypertension; Iran; Mortality; Years of life lost

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DEATH; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENDER; HUMAN; HYPERTENSION; IRAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PREHYPERTENSION; STRUCTURED QUESTIONNAIRE; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASE; MIDDLE AGED; MORTALITY; SYSTOLE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; SYSTOLE;

EID: 84924358270     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, et al. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med 2014; 17(5): 304-320.
2. Naghavi M, Shahraz S, Sepanlou SG, Dicker D, Naghavi P, Pourmalek F, et al. Health transition in Iran toward chronic diseases based on results of Global Burden of Disease 2010. Arch Iran Med 2014; 17(5): 321-335.
3. Shahraz S, Forouzanfar MH, Sepanlou SG, Dicker D, Naghavi P, Pourmalek F, et al. Population health and burden of disease profile of Iran among 20 countries in the region: from Afghanistan to Qatar and Lebanon. Arch Iran Med 2014; 17(5): 336-342.
4. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224-2260.
5. Farzadfar F, Danaei G, Namdaritabar H, Rajaratnam JK, Marcus JR, Khosravi A, et al. National and subnational mortality effects of metabolic risk factors and smoking in Iran: a comparative risk assessment Popul Health Metr. 2011; 9(1): 55.
6. WHO: STEP wise approach to surveillance (STEPS). Available from: URL: http://www.who.int/chp/steps/en/.
7. Karami M, Soori H, Monfared AB. Estimating the contribution of selected risk factors in attributable burden to stroke in iran Iran J Public Health 2012; 41(5): 91-96.
8. Ezzati M, Lopez AD, Rodgers A, Vander Hoom S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002; 360(9343): 1347-1360.
9. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Measuring the Global Burden of Disease and Risk Factors, 1990-2001, in Global Burden of Disease and Risk Factors, A.D. Lopez, et al., Editors. 2006: Washington (DC).
10. Lopez AD, Murray CJ. The global burden of disease, 1990-2020. Nat Med 1998; 4(11): 1241-1243.
11. Morrow RH, Hyder AA, Murray C J, Lopez AD. Measuring the burden of disease. Lancet. 1998; 352(9143): 1859-1861.
12. Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoom S. Comparative quantification of health risks conceptual framework and methodological issues. Popul Health Metr. 2003; 1(1): 1.
13. Khademi H, Etemadi A, Kamangar F, Nouraie M, Shakeri R, Abaie B, et al. Verbal autopsy: reliability and validity estimates for causes of death in the Golestan Cohort Study in Iran. PLoS One. 2010; 5(6): e11183.
14. Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort Profile: The Golestan Cohort Study - a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010; 39(1): 52-59.
15. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health. 2004.
16. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension J Hypertens. 2013; 31(10): 1925-1938.
17. Murray CJ, Ezzati M, Flaxman AD, Lim S, Lozano R, Michaud C, et al. GBD 2010: design, definitions, and metrics. Lancet. 2012; 380(9859): 2063-2066.
18. Islami F, Kamangar F, Nasrollahzadeh D, Aghcheli K, Sotoudeh M, Abedi-Ardekani B, et al. Socio - economic status and oesophageal cancer: results from a population - based case - control study in a high - risk area Int J Epidemiol. 2009; 38(4): 978-988.
19. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Tudor-Locke C, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. Med Sci Sports Exerc. 2011; 43(8): 1575-1581.
20. Newson RB. Attributable and unattributable risks and fractions and other scenario comparisons. Stata Journal. 2013; 13(4): 672-698.
21. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow - up in a population based cohort of Iran BMC Neurol. 2012; 12: 117.
22. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all - cause mortality attributable to diabetes: Tehran lipid and glucose study. J Endocrinol Invest. 2012; 35(1): 14-20.
23. Bozorgmanesh M, Hadaegh F, Mohebi R, Ghanbarian A, Eskandari F, Azizi F. Diabetic population mortality and cardiovascular risk attributable to hypertension: a decade follow - up from the Tehran Lipid and Glucose Study. Blood Press. 2013; 22(5): 317-324.
24. Whelton PK, Beevers DG, Sonkodi S. Strategies for improvement of awareness, treatment and control of hypertension: results of a panel discussion. J Hum Hypertens. 2004; 18(8): 563-565.
25. Malekzadeh MM, Etemadi A, Kamangar F, Khademi H, Golozar A, Islami F, et al. Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population. J Hypertens. 2013; 31(7): 1364-1371.
26. Sadeghi M, Shiri M, Roohafza H, Rakhshani F, Sepanlou SG, Sarrafzadegan N. Developing an appropriate model for self - care of hypertensive patients: first experience from EMRO. ARYAAtheroscler. 2013; 9(4): 232-240.
27. Jorgensen T, Jacobsen RK, Toft U, Aadahl M, Glumer C, Pisinger C. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ. 2014; 348: g3617.
28. Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010; 362(7): 590-599.
29. He FJ, MacGregor GA. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens. 2009; 23(6): 363-384.
30. Strazzullo P, D’Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta - analysis of prospective studies. BMJ. 2009; 339: b4567.
31. Taylor R, Hooper L, Ebrahim S. Dietary salt and cardiovascular disease. Lancet. 2011; 378(9808): 1993.
32. Taylor RS, Ashton KE, Moxham T, Hooper L, Ebrahim S. Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; (7): CD009217.
33. WHO. Guideline: Sodium intake for adults and children. 2012, World Health Organization (WHO): Geneva.
34. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003; 326(7404): 1419.
35. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle - aged individuals without cardiovascular disease (TIPS): a phase II, double - blind, randomised trial. Lancet. 2009; 373(9672): 1341-1351.
36. Yusuf S, Pais P, Sigamani A, Xavier D, Afzal R, Gao P, et al. Comparison of risk factor reduction and tolerability of a full - dose polypill (with potassium) versus low - dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS - 2) investigators. Circ Cardiovasc Qual Outcomes. 2012; 5(4): 463-471.
37. Malekzadeh F, Pourshams A, Marshall T, The preventive polypill - much promise, insufficient evidence. Arch Iran Med 2007; 10(3): 430-431.
38. Rastegarpanah M, Malekzadeh F, Thomas GN, Mohagheghi A, Cheng KK, Marshall T. Anew horizon in primary prevention of cardiovascular disease, can we prevent heart attack by “heart polypill”? Arch Iran Med 2008; 11(3): 306-313.
39. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, et al. A pilot double - blind randomised placebo - controlled trial of the effects of fixed - dose combination therapy (‘polypill’) on cardiovascular risk factors. Int J Clin Pract. 2010; 64(9): 1220-1227.
40. Sepanlou SG, Farzadfar F, Jafari E, Danaei G. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta - analyses and mortality estimation. Arch Iran Med 2012; 15(9): 531-537.
41. Sepanlou SG, Kamangar F, Poustchi H, Malekzadeh R. Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action Arch Iran Med 2010; 13(4): 340-350.
42. Sepanlou SG, Poustchi H, Kamangar F, Malekzadeh R. Effectiveness and feasibility of lifestyle and low - cost pharmacologic interventions in the prevention of chronic diseases: a review. Arch Iran Med. 2011; 14(1): 46-53.